WSTWEST PHARMACEUTICAL SERVICES INC
Surgical & Medical Instruments & Apparatus
- Revenue
- $3.1B
- 6.3% YoY
- Operating margin
- 19.0%
- 3.4% YoY
- EBITDA
- $756M
- 4.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.3×
- −$261M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear153% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear26% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B | 6.3% |
| Operating income | $752M | $734M | $676M | $570M | $585M | 2.6% |
| Net income | $662M | $586M | $593M | $493M | $494M | 0.2% |
| Operating cash flow | $584M | $724M | $777M | $653M | $755M | 16% |
| Capex | $253M | $285M | $362M | $377M | $286M | 24% |
| Stock-based comp | $38M | $24M | $23M | $19M | $24M | 27% |
| Buybacks | $137M | $203M | $438M | $561M | $134M | 76% |
| Dividends | $51M | $54M | $57M | $59M | $61M | 3.6% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $5M · 6
- Net
- −$5M
Pay vs performance
No pay-versus-performance disclosure yet.